MDEA

The onset of MDEA unfolds over forty-five minutes to an hour, arriving with a gentler hand than its more famous sibling. A warmth builds in the torso, the heart rate rises modestly, and there is a gradual expansion of emotional availability. The come-up lacks the sudden, revelatory quality of MDMA. Instead, the transition into the empathogenic state is smooth and measured, a slow opening of emotional doors rather than a dramatic throwing open of the shutters.

As the effects develop, MDEA produces an empathogenic experience that is recognizably related to MDMA but tempered in its expression. Emotional warmth is genuine and inviting but lacks the overwhelming, almost forceful quality that defines the MDMA peak. Conversations deepen and become more honest, but the drive to confess, to bare the soul, is less insistent. Social barriers lower, affection comes easily, and there is a comfortable sense of trust and openness. Touch is enhanced pleasantly, and music carries more emotional weight. The stimulant component is mild, enough to keep the user alert and engaged but not enough to drive physical activity. The body is warm and relaxed, with moderate jaw tension and mild pupil dilation.

At the peak, roughly ninety minutes to two hours in, MDEA occupies a space slightly below MDMA in intensity and slightly above it in subtlety. The emotional openness is present without being overwhelming. The euphoria is moderate and warm rather than ecstatic. There is a contemplative quality to the peak, a tendency toward reflective conversation and quiet intimacy rather than exuberant socializing. Some users describe the headspace as more mature or grounded than MDMA, less likely to produce the wide-eyed, indiscriminate love that characterizes higher-dose MDMA experiences. Physical side effects are proportionally milder.

The decline begins around three to four hours in and is smooth. The empathogenic warmth fades gradually, and there is a gentle return to baseline emotional functioning. The comedown is milder than MDMA: less serotonergic depletion, less fatigue, and less emotional flatness in the following days. Sleep comes without significant difficulty, and the next day may carry only a faint quietness. The total experience is often described as MDMA's more subtle, more reflective cousin, an empathogenic experience for those who want the warmth without the spectacle.

MDEA acts as a releasing agent and reuptake inhibitor of the monoamine neurotransmitters serotonin, dopamine and noradrenaline

Short-term physical health risks of MDEA consumption include dehydration, insomnia, hyperthermia, and hyponatremia. Continuous activity without sufficient rest or rehydration may cause body temperature to rise to dangerous levels, and loss of fluid via excessive perspiration puts the body at further risk as the stimulatory and euphoric qualities of the drug may render the user oblivious to their energy expenditure for quite some time. Diuretics such as alcohol may exacerbate these risks further.exact toxic dosage is unknown, but considered to be far greater than its active dose.

• Neurotoxicity

As with MDMA, the neurotoxicity of MDEA use has long been the subject of debate. Scientific study has resulted in the general agreement that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of MDEA is likely to be neurotoxic and cardiotoxic in some form.

Like other powerful serotonin releasing agents, MDEA is thought to cause down-regulation of serotonin reuptake transporters in the brain. The rate at which the brain recovers from serotonergic changes is unclear. One study demonstrated lasting serotonergic changes in some animals exposed to MDMA, which likely applies to MDEA as well. Other studies have suggested that the brain may recover from serotonergic damage.

• Cardiotoxicity

Like with MDMA, the long-term heavy use of MDEA is likely similarly cardiotoxic, leading to valvulopathy through its actions on the 5-HT2B receptor. In one study, 28% of long-term MDMA users (2-3 doses per week for a mean of 6 years, mean of age 24.3 years) had developed clinically evident valvular heart disease.

It is strongly recommended that one use harm reduction practices when using this substance.

As with other stimulants,moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.with prolonged and repeated use. This results in users having to administer increasingly larger doses to achieve the same effects. After that,1-1.52-3 months to be back at baseline (in the absence of further consumption). MDEA presents cross-tolerance with Cross-all dopaminergic and serotonergic stimulants and entactogens, meaning that after the consumption of MDEA all of these will have a reduced effect. -Stimulants** - The neurotoxic effects of MDEA may be increased when combined with other stimulants. -Cocaine** - This combination may increase strain on the heart.

• Serotonin syndrome risk

There is an increased risk of serotonin syndrome when MDEA is taken with many antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Additionally, if MDEA is taken with SSRIs and SNRIs, the MDEA will be significantly less powerful or may have no distinguishable effects at all.

Internationally, MDEA is part of the the Convention on Psychotropic Substances of 1971 as a Schedule I substance. (MDE)

• Austria: MDEA is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).

• Brazil: MDEA is illegal to possess, produce or sell as it is listed on Portaria SVS/MS nº 344 as "MDE".

• Canada: MDEA is listed on the CSDA in Schedule I.

• France: MDEA is scheduled as a "stupéfiant", i.e. a recognized drug of abuse. It is illegal to possess, buy, sell or manufacture.

• Germany: MDEA is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of April 15, 1991. It is illegal to manufacture, possess, import, export, buy, sell, procure or to dispense it without a license. (MDE)

• Switzerland: MDEA is a controlled substance specifically named under Verzeichnis D.

• United Kingdom: MDEA is a Class A drug.

• United States: MDEA is a Schedule I drug.

• Responsible use

• Entactogen

• Stimulant

• Phenethylamine

• MDMA

• MDA

• MDEA (Wikipedia)

• MDEA (Erowid Vault)

• MDEA (PiHKAL / Isomer Design)

• MDEA (DrugBank)

• Freudenmann RW, Spitzer M (2004). The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). CNS Drug Reviews. 10 (2): 89–116. https://doi.org/10.1111/j.1527-3458.2004.tb00007.x. PMID 15179441.

In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA before it was made a Schedule I substance two years later on August 13, 1987 under the Federal Analogue Act.

Short-term physical health risks of MDEA consumption include dehydration, insomnia, hyperthermia, and hyponatremia. Continuous activity without sufficient rest or rehydration may cause body temperature to rise to dangerous levels, and loss of fluid via excessive perspiration puts the body at further risk as the stimulatory and euphoric qualities of the drug may render the user oblivious to their energy expenditure for quite some time. Diuretics such as alcohol may exacerbate these risks further.exact toxic dosage is unknown, but considered to be far greater than its active dose.

• Neurotoxicity

As with MDMA, the neurotoxicity of MDEA use has long been the subject of debate. Scientific study has resulted in the general agreement that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of MDEA is likely to be neurotoxic and cardiotoxic in some form.

Like other powerful serotonin releasing agents, MDEA is thought to cause down-regulation of serotonin reuptake transporters in the brain. The rate at which the brain recovers from serotonergic changes is unclear. One study demonstrated lasting serotonergic changes in some animals exposed to MDMA, which likely applies to MDEA as well. Other studies have suggested that the brain may recover from serotonergic damage.

• Cardiotoxicity

Like with MDMA, the long-term heavy use of MDEA is likely similarly cardiotoxic, leading to valvulopathy through its actions on the 5-HT2B receptor. In one study, 28% of long-term MDMA users (2-3 doses per week for a mean of 6 years, mean of age 24.3 years) had developed clinically evident valvular heart disease.

It is strongly recommended that one use harm reduction practices when using this substance.

As with other stimulants,moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.with prolonged and repeated use. This results in users having to administer increasingly larger doses to achieve the same effects. After that,1-1.52-3 months to be back at baseline (in the absence of further consumption). MDEA presents cross-tolerance with Cross-all dopaminergic and serotonergic stimulants and entactogens, meaning that after the consumption of MDEA all of these will have a reduced effect. -Stimulants** - The neurotoxic effects of MDEA may be increased when combined with other stimulants. -Cocaine** - This combination may increase strain on the heart.

• Serotonin syndrome risk

There is an increased risk of serotonin syndrome when MDEA is taken with many antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Additionally, if MDEA is taken with SSRIs and SNRIs, the MDEA will be significantly less powerful or may have no distinguishable effects at all.

Internationally, MDEA is part of the the Convention on Psychotropic Substances of 1971 as a Schedule I substance. (MDE)

• Austria: MDEA is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).

• Brazil: MDEA is illegal to possess, produce or sell as it is listed on Portaria SVS/MS nº 344 as "MDE".

• Canada: MDEA is listed on the CSDA in Schedule I.

• France: MDEA is scheduled as a "stupéfiant", i.e. a recognized drug of abuse. It is illegal to possess, buy, sell or manufacture.

• Germany: MDEA is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of April 15, 1991. It is illegal to manufacture, possess, import, export, buy, sell, procure or to dispense it without a license. (MDE)

• Switzerland: MDEA is a controlled substance specifically named under Verzeichnis D.

• United Kingdom: MDEA is a Class A drug.

• United States: MDEA is a Schedule I drug.

• Responsible use

• Entactogen

• Stimulant

• Phenethylamine

• MDMA

• MDA

• MDEA (Wikipedia)

• MDEA (Erowid Vault)

• MDEA (PiHKAL / Isomer Design)

• MDEA (DrugBank)

• Freudenmann RW, Spitzer M (2004). The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). CNS Drug Reviews. 10 (2): 89–116. https://doi.org/10.1111/j.1527-3458.2004.tb00007.x. PMID 15179441.